Table 2.

Platelet transfusions

Pre-ULR group
Post-ULR group
P
No. of platelet transfusions/pt*    
    All patients   28 ± 31   17 ± 20   < .001† 
    Chemotherapy or supportive care patients     
        ALL   19 ± 18   15 ± 9   .398† 
        AML   27 ± 23   20 ± 19   .044† 
        Supportive care   33 ± 45   9 ± 9   .100† 
    Stem cell transplantation patients     
        ALLO RD   25 ± 28   17 ± 17   .051† 
        ALLO VUD   51 ± 40   34 ± 32   .044† 
        AUTO BM   36 ± 41   18 ± 19   .023† 
        AUTO PB   10 ± 10   5 ± 4   < .001† 
No. of donor exposures/pt*  107 ± 119   61 ± 69   < .001† 
No. of platelet transfusions (%)    
        Total   8698   5204   
        Pooled RDP   6002 (69)   3422 (66)   
        Random SDP   2169 (25)   1603 (31)   
        HLA-matched SDP   527 (7)   147 (3)   < .001‡ 
Platelets per transfusion,* × 1011  3.9 ± 1.8   3.9 ± 1.8   .873† 
CCI*  12.6 ± 8.6   11.7 ± 7.0   .20† 
Pts receiving HLA transfusions, no. (%)   44 (16)   16 (5)   < .001‡ 
Duration of follow-up, d    
        Median (range)
 		 48 (2-1083)
 		 79 (2-1025)
 		 .004†
 
Pre-ULR group
Post-ULR group
P
No. of platelet transfusions/pt*    
    All patients   28 ± 31   17 ± 20   < .001† 
    Chemotherapy or supportive care patients     
        ALL   19 ± 18   15 ± 9   .398† 
        AML   27 ± 23   20 ± 19   .044† 
        Supportive care   33 ± 45   9 ± 9   .100† 
    Stem cell transplantation patients     
        ALLO RD   25 ± 28   17 ± 17   .051† 
        ALLO VUD   51 ± 40   34 ± 32   .044† 
        AUTO BM   36 ± 41   18 ± 19   .023† 
        AUTO PB   10 ± 10   5 ± 4   < .001† 
No. of donor exposures/pt*  107 ± 119   61 ± 69   < .001† 
No. of platelet transfusions (%)    
        Total   8698   5204   
        Pooled RDP   6002 (69)   3422 (66)   
        Random SDP   2169 (25)   1603 (31)   
        HLA-matched SDP   527 (7)   147 (3)   < .001‡ 
Platelets per transfusion,* × 1011  3.9 ± 1.8   3.9 ± 1.8   .873† 
CCI*  12.6 ± 8.6   11.7 ± 7.0   .20† 
Pts receiving HLA transfusions, no. (%)   44 (16)   16 (5)   < .001‡ 
Duration of follow-up, d    
        Median (range)
 		 48 (2-1083)
 		 79 (2-1025)
 		 .004†
 

Pt indicates patient; ALLO, allogeneic; RD, related donor; VUD, volunteer unrelated donor; AUTO, autologous; PB, peripheral blood progenitors; RDP, random donor platelets; SDP, single-donor platelets; and CCI, corrected count increment.

*

Mean ± SD.

†

Student unpaired t test.

‡

Chi-square test.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal